We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

96 hedge funds and large institutions have $107M invested in Palvella Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more capital invested

Capital invested by funds: $85.9M → $107M (+$21.2M)

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

19% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 26

1% more funds holding

Funds holding: 95 → 96 (+1)

0.01% less ownership

Funds ownership: 0.84% → 0.82% (-0.01%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
96
Holders Change
+1
Holders Change %
+1.05%
% of All Funds
1.97%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
12
Increased
31
Reduced
26
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CS
Candriam SCA
Luxembourg
+$2.51M
2
WP
Woodline Partners
California
+$1.86M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$1.48M
4
BlackRock
BlackRock
New York
+$621K
5
PIM
Platinum Investment Management
Australia
+$599K

Top Sellers

1
BI
BVF Inc
California
-$8.06M
2
CA
Corriente Advisors
Texas
-$4.42M
3
Morgan Stanley
Morgan Stanley
New York
-$980K
4
EC
EcoR1 Capital
California
-$602K
5
GCP
GSA Capital Partners
United Kingdom
-$414K
Name Holding Trade Value Shares
Change 		Change in
Stake
Cerity Partners
26
Cerity Partners
New York
$590K – – –
SPC
27
Sigma Planning Corp
Michigan
$563K +$254K +1,085 +92%
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Quebec, Canada
$559K – – –
AQR Capital Management
29
AQR Capital Management
Connecticut
$546K -$13.3K -57 -3%
N
30
Nuveen
North Carolina
$508K -$26.7K -114 -5%
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$481K +$173K +739 +61%
Wells Fargo
32
Wells Fargo
California
$457K +$57.1K +244 +15%
SO
33
STRS Ohio
Ohio
$433K – – –
Bank of New York Mellon
34
Bank of New York Mellon
New York
$412K – – –
Charles Schwab
35
Charles Schwab
California
$392K +$27.1K +116 +8%
Los Angeles Capital Management
36
Los Angeles Capital Management
California
$392K +$190K +812 +106%
VC
37
Voss Capital
Texas
$387K -$88.6K -379 -20%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$348K +$29.2K +125 +10%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$311K +$197K +841 +203%
6CM
40
683 Capital Management
New York
$279K – – –
Millennium Management
41
Millennium Management
New York
$269K +$254K +1,086 New
CS
42
Credit Suisse
Switzerland
$253K +$14.5K +62 +6%
Two Sigma Investments
43
Two Sigma Investments
New York
$253K +$104K +444 +77%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$220K – – –
UBS Group
45
UBS Group
Switzerland
$215K -$19.4K -83 -9%
PAM
46
Panagora Asset Management
Massachusetts
$215K +$28.1K +120 +16%
Deutsche Bank
47
Deutsche Bank
Germany
$211K +$24.6K +105 +14%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$209K +$12.6K +54 +7%
Morgan Stanley
49
Morgan Stanley
New York
$202K -$980K -4,189 -84%
RCG
50
Rock Creek Group
District of Columbia
$201K -$59.4K -254 -24%
1
2
3 4 5

PVLA Hedge Fund Activity: Q2 2020 in Review

96 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2020, worth a combined $107M — up 25% from $85.9M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PVLA positions and 10 closed out — a net gain of 2 holders — while 31 added to existing stakes and 26 trimmed.

The largest buyer was Candriam SCA, adding an estimated $2.51M. The largest seller was BVF Inc, cutting an estimated $8.06M.

  • 96 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2020, up from 95 in Q1 2020.
  • Funds reported $107M of Palvella Therapeutics stock for Q2 2020, up 25% quarter-over-quarter.
  • 12 funds opened new Palvella Therapeutics positions in Q2 2020 and 10 closed out, a net change of +2 holders.
  • The largest Palvella Therapeutics buyer in Q2 2020 was Candriam SCA, an estimated $2.51M added.
  • The largest Palvella Therapeutics seller in Q2 2020 was BVF Inc, an estimated $8.06M sold.

Based on aggregated 13F filings for Q2 2020.